title: Association of TCF7L2 gene variants with low GAD autoantibody titre in LADA subjects (NIRAD Study 5).
abstract: OBJECTIVE
  We previously demonstrated the presence of two different populations among adult-onset autoimmune diabetes (latent autoimmume diabetes of adults; LADA) having high or low titre of antibodies to glutamic acid decarboxylase (GADA). The transcription factor 7-like 2 (TCF7L2) gene has been recognized as the major gene associated with Type 2 diabetes. The aim of the present study was to evaluate whether the phenotypic heterogeneity of LADA based on GADA titre is associated with TCF7L2 polymorphisms.
  
  
  METHODS
  Two hundred and fifty patients identified as LADA, divided into two subgroups with low (< or = 32 arbitrary units) or high (> 32 units) GADA titre, 620 subjects with Type 2 diabetes [from the Non-Insulin Requiring Autoimmune Diabetes (NIRAD) study cohort of 5330 subjects] in addition to 551 consecutive cases of Type 1 diabetes and 545 normoglycaemic subjects were analysed for the rs12255372 and rs7903146 polymorphisms of the TCF7L2 gene using Taqman.
  
  
  RESULTS
  The genotype and allele distributions of the two polymorphisms revealed similar frequencies in subjects with low GADA titre and Type 2 diabetes. High GADA titre, Type 1 diabetes and controls also showed comparable frequencies. A significant increase of GT/TT genotypes of the rs12255372 single-nucleotide polymorphism (SNP) and CT/TT genotypes of the rs7903146 SNP was observed in low GADA titre and Type 2 diabetes compared with high GADA titre, Type 1 diabetes and controls (P < or = 0.04 for both comparisons). The risk alleles of both variants were increased in low GADA titre and Type 2 diabetes compared with high GADA titre, Type 1 diabetes and control subjects (P < 0.02 for all comparisons).
  
  
  CONCLUSIONS
  TCF7L2 common genetic variants of susceptibility are associated only with low GADA antibody titre in LADA patients.
authors.affiliation: Department of Clinical Sciences, Sapienza University, Rome, Italy.
authors.forename: S
authors.initials: S
authors.lastname: Zampetti
authors.forename: M
authors.initials: M
authors.lastname: Spoletini
authors.forename: A
authors.initials: A
authors.lastname: Petrone
authors.forename: M
authors.initials: M
authors.lastname: Capizzi
authors.forename: M L
authors.initials: ML
authors.lastname: Arpi
authors.forename: C
authors.initials: C
authors.lastname: Tiberti
authors.forename: S
authors.initials: S
authors.lastname: Di Pietro
authors.forename: E
authors.initials: E
authors.lastname: Bosi
authors.forename: P
authors.initials: P
authors.lastname: Pozzilli
authors.forename: F
authors.initials: F
authors.lastname: Giorgino
authors.forename: R
authors.initials: R
authors.lastname: Buzzetti
mesh_terms: D000328:Adult; D017668:Age of Onset; D001323:Autoantibodies / Q000276:immunology; D016022:Case-Control Studies; D003922:Diabetes Mellitus, Type 1 / Q000235:genetics* / Q000276:immunology; D003924:Diabetes Mellitus, Type 2 / Q000235:genetics* / Q000276:immunology; D005260:Female; D020022:Genetic Predisposition to Disease; D005968:Glutamate Decarboxylase / Q000235:genetics* / Q000276:immunology; D006801:Humans; D008297:Male; D008875:Middle Aged; D011110:Polymorphism, Genetic; D013223:Statistics as Topic; D058118:Transcription Factor 7-Like 2 Protein / Q000235:genetics / Q000276:immunology
chemical_list: D001323:Autoantibodies; D058118:Transcription Factor 7-Like 2 Protein; D005968:Glutamate Decarboxylase